The French Competition Authority rejects a claim for interim measures but holds that a pharmaceutical company may be at fault for promoting the differences between its product and competing for generic products whereas such differences have no therapeutic value (Sanofi-Aventis)

KEYWORDS
Reference

French Competition Authority, Sanofi-Aventis, Decision n° 10-D-16, 17 May 2010 (French)

Since 1998, the Sanofi-Aventis France laboratory has been marketing an antiplatelet medication, Plavix(r), whose intellectual property protection expired on 15 July 2008 in Europe, with the exception of the rights protecting clopidogrel salt used in Plavix(r) and the clopidogrel-aspirin combination used in the treatment of acute coronary syndrome (ACS). A dozen or so generic specialities, including that of Sanofi-Aventis, have received a marketing authorisation. To promote its

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Vogel & Vogel (Paris)
    France 94 contributions 118033 visites

Citation

Joseph Vogel, The French Competition Authority rejects a claim for interim measures but holds that a pharmaceutical company may be at fault for promoting the differences between its product and competing for generic products whereas such differences have no therapeutic value (Sanofi-Aventis), 17 mai 2010, e-Competitions May 2010, Art. N° 31735

Visites 987

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues